Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Asthma
What is your preferred biologic for an asthmatic patient with a T2 low phenotype and who is a smoker?
Related Questions
Have you observed adverse mental health side effects in patients who start montelukast?
Have you experienced any issues with Alvesco inhalers getting clogged repeatedly?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
Do you feel high dose Symbicort or Dulera is appropriate to use for SMART despite these doses not being studied in clinical trials?
What is the rationale/evidence to support doing 4 puffs of albuterol vs. 2 puffs for a reversibility study?
Is there any genetic testing available for the CDHR3 receptor?
What is your preferred biologic in children and adolescents with T2 high asthma?
Should in-office oscillometry for lung function measurements be utilized in pediatric patients who are unable to reliably perform spirometry?
What treatment approach do you suggests for a patient with nasal polyp disease and asthma who was improved on dupilumab, but over last 2 years has begun to have increased nasal symptoms and rising eosinophil counts?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
